Selection and characterization of a replication-competent human immunodeficiency virus type 1 variant encoding C-terminally truncated Env

AIDS Research and Human Retroviruses

Volumn 22, Issue 1, 2006, Pages 57-65

  Holtkotte, Denise ^a   Pfeiffer, Tanya ^a   Pisch, Thorsten ^a   Bosch, Valerie ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARAGINE; LYSINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; ENVELOPE GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS REPLICATION;

CELL LINE; DNA, VIRAL; GENE DELETION; GENES, ENV; HIV-1; HUMANS; VIRUS REPLICATION;

EID: 32044434165     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.57     Document Type: Article

References (34)

1. Haffar OK, Dowbenko DJ, and Berman PW: The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes. Virology 1991;180:439-441.
2. Chernomordik L, Chanturiya AN, Suss-Toby E, Nora E, and Zimmerberg J: An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol 1994;68:7115-7123.
3. Kliger Y and Shai Y: A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 1997;36:5157-5169.
4. Ohno H, Stewart J, Fournier MC, et al.: Interaction of tyrosinebased sorting signals with clathrin-associated proteins. Science 1995;269:1872-1875.
5. Ohno H, Aguilar RC, Fournier MC, Hennecke S, Cosson P, and Bonifacino JS: Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 1997;238:305-315.
6. Murakami T and Freed EO: Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol 2000;74:3548-3554.
7. Freed EO and Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996;70:341-351.
8. Cosson P: Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J 1996;15:5783-5788.
9. Wyma DJ, Kotov A, and Aiken C: Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol 2000;74:9381-9387.
10. Srinivas SK, Srinivas RV, Anantharamaiah GM, Compans RW, and Segrest JP: Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem 1993;268:22895-22899.
11. Kim EM, Lee KH, and Kim JW: The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. Mol Cells 1999;9:281-285.
12. Zhang H, Wang L, Kao S, et al.: Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol 1999;9:1271-1274.
13. Kim JT, Kim EM, Lee KH, Choi JE, Jhun BH, and Kim JW: Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin. Biochem Biophys Res Commun 2002;291:1239-1244.
14. Wilk T, Pfeiffer T, and Bosch V: Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 1992;189:167-177.
15. Dubay JW, Roberts SJ, Hahn BH, and Hunter E: Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol 1992;66:6616-6625.
16. Gabuzda DH, Lever A, Terwilliger E, and Sodroski J: Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 1992;66:3306-3315.
17. Yu X, Yuan X, McLane MF, Lee TH, and Essex M: Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol 1993;67:213-221.
18. Murakami T and Freed EO: The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci USA 2000;97:343-348.
19. Freed EO and Martin MA: Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995;69:1984-1989.
20. Mammano F, Kondo E, Sodroski J, Bukovsky A, and Gottlinger HG: Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol 1995;69:3824-3830.
21. Akari H, Fukumori T, and Adachi A: Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J Virol 2000;74:4891-4893.
22. Piller SC, Dubay JW, Derdeyn CA, and Hunter E: Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: Effects on glycoprotein incorporation and infectivity. J Virol 2000;74:11717-11723.
23. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
24. Ratner L, Haseltine W, Patarca R, et al.: Complete nucleotide sequence of the AIDS virus, HTLV-111. Nature 1985;313:277-284.
25. Pear WS, Nolan GP, Scott ML, and Baltimore D: Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-8396.
26. Wei X, Decker JM, Liu H, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
27. Derdeyn CA, Decker JM, Sfakianos JN, et al.: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000;74:8358-8367.
28. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
29. Abacioglu YH, Fouts TR, Laman JD, et al.: Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994;10:371-381.
30. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates - definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
31. Shimizu H, Morikawa S, Yamaguchi K, et al.: Shorter size of transmembrane glycoprotein of an HIV-1 isolate. AIDS 1990;4:575-576.
32. Shimizu H, Hasebe F, Tsuchie H, Morikawa S, Ushijima H, and Kitamura T: Analysis of a human immunodeficiency virus type 1 isolate carrying a truncated transmembrane glycoprotein. Virology 1992;189:534-546.
33. Jones DR, Suzuki K, and Piller SC: A 100-amino acid truncation in the cytoplasmic tail of glycoprotein 41 in the reference HIV type 1 strain RF. AIDS Res Hum Retroviruses 2002;18:513-517.
34. Spies CP and Compans RW: Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 1994;203:8-19.